A dual PI3 kinase/mtor inhibitor reveals emergent efficacy in glioma

Size: px

Start display at page:

Download "A dual PI3 kinase/mtor inhibitor reveals emergent efficacy in glioma"

Abraham Gilbert
6 years ago
Views:

Supplemental data A dual PI3 kinase/mtor inhibitor

fails to induce targets associated with DNA damage

(0.5 µm, 24h), exposed to UVC (20 J/m 2 ) or

A: Cells were fixed and stained with antisera

cells and cells treated with showed little

1 Supplemental data A dual PI3 kinase/mtor inhibitor reveals emergent efficacy in glioma Qi-Wen Fan, Zachary A. Knight, David D. Goldenberg, Wei Yu, Keith E. Mostov, David Stokoe, Kevan M. Shokat, and William A. Weiss Figure S1. fails to induce targets associated with DNA damage check-points A and B: U87MG cells were treated with (0.5 µm, 24h), exposed to UVC (20 J/m 2 ) or treated with both agents as shown. A: Cells were fixed and stained with antisera against p-γh2ax (red staining) and counterstained with To- Pro-3 iodide (blue). In contrast to cells treated with UVC, control cells and cells treated with showed little activation of p-γh2ax. Scale bar corresponds to 100 µm. B: Lysates were subjected to immunoblot analysis with antisera indicated. UVC treatment resulted in activation of both p53 and p-γh2ax. In contrast, failed to activate either of these DNA check-point markers, either as monotherapy, or when combined with UVC. These data suggest that does not significantly activate DNA-repair dependent check-points associated with increasing the mutation rate. A Control UVC B p-p53(ser15) p53 p-γh2ax(ser139) UVC + H2AX + + +

2 Figure S2. Flow cytometry using isoform-selective inhibitors of p110α against a glioma cell line U373M glioma cells were treated with isoform-selective inhibitors shown (0.5 µm) or with (10 µm) for 24h. Nuclei from trypsinized cells were stained with propidium iodide, and analyzed by FACScan. Numbers represent percentages in G 0 G 1, S, and G 2 M phases of the cell cycle. G 0 G 1 : 52 G 2 M: 17 G 0 G 1 : 59 S: 19 G 2 M: 22 PIK-64 S: 32 PIK-85 G 0 G 1 : 52 S: 34 G 2 M: 13 PIK-90 G 0 G 1 : 60 G 2 M: 10 PIK-93 G 0 G 1 : 50 S: 36 G 2 M: 14 PIK-112 G 0 G 1 : 55 S: 27 G 2 M: 18 G 0 G 1 : 70 S: 22 G 2 M: 8 PIK-124 TGX-115 S: 32 PIK-73 TGX-286 PIK-108 G 0 G 1 : 55 S: 30 PIK-39 S: 32 Rapamycin G 0 G 1 : 48 S: 36

3 Figure S3. Comparison of isoform-selective inhibition and sirna directed against p110α or p110β U87MG glioma cell lines were treated with isoform-selective inhibitors PIK-90 (p110α) or TGX-286 (p110β) at 0.5 µm, with sirna directed against p110α (Czauderna et al., 2003), p110β (Santa Cruz), or with a control scrambled sirna (Elbashir et al., 2001). A: Lysates were immunoblotted for signaling intermediates shown. Whereas all active agents blocked p- Akt, sirna against p110β was unique in reducing levels of p85α, a result also observed by others interrogating the impact of p110β loss genetically (Brachmann et al., 2005). B: Nuclei from trypsinized cells were stained with propidium iodide, and analyzed by FACScan. Numbers represent percentages in G 0 G 1, S, and G 2 M phases of the cell cycle. In contrast to results using small molecule inhibitors of p110β, sirna directed against p110β led to proliferative arrest. Although this arrest could in-part be attributable to decreased levels of p110β, other variables contributing to this arrest include decreased levels of free p85, and alterations in the ratio of p110:p85, both of which are key regulators of PI3-kinase signaling (reviewed in (Hennessy et al., 2005)).

4 Figure S4. inhibits phosphorylation of Akt in a dose dependent manner, and induces cell cycle arrest in a panel of human glioma cell lines irrespective of p53 or PTEN status A and B: U87MG (PTEN mutant) and LN229 cells (PTEN wild-type) were treated with ( µm) for 24h. Lysates were subjected to immunoblot analysis with antisera indicated. C and D: Proliferation was visualized by crystal-violet staining of cells after treatment with for 48h (top panels) Cell cycle distribution was analyzed by flow cytometric analysis after treatment for 24h (bottom panels). Percentage of cells in G 0 /G 1, S, and G 2 M phases of the cell cycle are indicated. Although levels of p-akt were increased in the PTEN mutant cell line, both cell lines showed similar dose-response to, irrespective of PTEN status. E: Human glioma cell lines indicated were treated with (0.5 µm) or (10 µm) for 24h. Cells were harvested, lysed and subjected to immunoblot analysis with antisera indicated.

5 Figure S5. Isoform-selective inhibitors of p110α show activity against a panel of glioma cell lines Glioma cell lines indicated were treated with isoform-selective inhibitors shown (0.5 µm) or with (10 µm) for 24h. Nuclei from trypsinized cells were stained with propidium iodide, and analyzed by FACScan. Numbers represent percentages in G 0 G 1, S, and G 2 M phases of the cell cycle.

6 Table S1. G 0 G 1 arrest in glioma cell lines, irrespective of p53 Cell line U87 P53 status PTEN Treatment or PTEN status Cell Cycle Distribution G 0 G 1 S G 2 M U87:² EGFR U87:EGFR U373 LN299 SF188 LN-Z308 A1207 SF763 SF Cells were treated with (control), (0.5 µm), or (10 µm) for 24 h. There are no known glioma cell lines that carry gain of function mutations in p110α. The frequency of these mutations in glioma is currently uncertain. Abbreviations;, Wild type;, Mutant.

Validation & Assay Performance Summary

Validation & Assay Performance Summary CellSensor DBE-bla MDA-MB-468 Cell Line Cat. no. K1814 Pathway Description The phosphatidylinositol-3-kinase (PI3K) signaling cascade is essential for cell growth